Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
Mantle cell lymphoma is a biologically heterogeneous B‑cell lymphoma characterized by highly variable clinical outcomes.
This review discusses the evolution of risk stratification and emerging treatment approaches for mantle cell lymphoma, highlighting the need for personalized and risk‑adapted treatment strategies.
The heterogeneity of mantle cell lymphoma and its variable clinical outcomes underscore the importance of accurate risk stratification to guide therapy and improve patient prognosis.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa
- Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies